Sheeba K Thomas
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sheeba K Thomas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01283997 · Prevention of Treatment Induced Neuropathy in Multiple MyelomaM.D. Anderson Cancer Center · completed · Myeloma · principal investigator
- Ph1NCT01198067 · Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaM.D. Anderson Cancer Center · terminated · Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- TARGETING NF-KB ACTIVATION IN REGULATION OF SYMPTOMS IN PATIENTS WITH MULTIPLEP01CA124787 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Bharat B Aggarwal · fiscal years 2008 to 2012Named on NCT01283997
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:20 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.Lancet Haematol · 2020144 citationsRCR 6.3
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.Br J Haematol · 2013138 citationsRCR 3.7
- Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.Int J Geriatr Psychiatry · 200783 citationsRCR 2.9
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol · 201975 citationsRCR 3.1
- Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.Neurology · 200756 citationsRCR 1.8
- Treatment persistency with rivastigmine and donepezil in a large state medicaid program.J Am Geriatr Soc · 200540 citationsRCR 1.3
- Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.Blood Cancer J · 201633 citationsRCR 1.0
- Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.Bone Marrow Transplant · 201926 citationsRCR 1.1
- A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Blood Cancer J · 201920 citationsRCR 0.7
- Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.Ann Hematol · 201719 citationsRCR 0.6